On our screens:Cheap stocks by free cash flow yieldQuality compoundersLow-volatility growth stocksQuality at a reasonable price
The financials
Labcorp by the numbers
Labcorp (LH) reported revenue of $3.54B in Q1 2026 (quarter ended Mar 31, 2026), up 5.8% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $278M (7.9% of revenue). For the full year FY2025, revenue was $14.0B (+7.2% year on year) and net income $877M. Its largest segment in Jun 2026 was Diagnostics at $2.90B, 78% of the disclosed total, well ahead of Biopharma Laboratory Services at 22%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $3.54B | $3.35B | +5.8% |
| Gross profit | $1.01B | $948M | +6.9% |
| Operating income | $381M | $326M | +17% |
| Net income | $278M | $213M | +31% |
| Diluted EPS | $3.35 | $2.52 | +33% |
| Operating | Revenue | Share |
|---|---|---|
| Diagnostics | $2.90B | 78% |
| Biopharma Laboratory Services | $836M | 22% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Jun 2026Total $3.74B (+5.5%)
Biopharma Laboratory Services grew +6.5% year on yearDiagnostics +5.5% year on year
Segment Latestquarter on quarteryear on year
- Diagnostics$2.90B$2.90BQoQ +5.0%year on year +5.5%+5.0%+5.5%
- Biopharma Laboratory Services$836.2M$836.2MQoQ +7.1%year on year +6.5%+7.1%+6.5%
Diagnostics & Research
The closest names by size in the same industry